Uso do plasma rico em plaquetas na cicatrização cirúrgica: evidências e aplicações clínicas
Revista ft · 07.08.2026 · 30 (161) · 01-12
DOI: 10.69849/30c4gz39 ↗Kurz gefasst
Fachartikel in der Zeitschrift Revista ft, online erschienen am 07.08.2026. Verfasst von Luca Rodrigues Pereira Mundim und 9 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The healing of surgical and chronic wounds represents a growing challenge for global health systems, with estimates indicating that between 1% and 2% of the world population suffers from difficult-to-heal wounds, generating annual costs ranging from 28 to 96 billion dollars in the United States. Given the limitations of conventional treatments, Platelet-Rich Plasma (PRP) has emerged as an autologous, biomimetic, and minimally invasive adjuvant therapy, obtained through centrifugation of the patient’s own blood and enriched with growth factors such as PDGF, TGF-β, VEGF, and EGF. This article aimed to elucidate and evaluate, in light of the most recent scientific evidence, the biological mechanisms, clinical efficacy, and application protocols of PRP in the healing of surgical and chronic wounds. This is an integrative literature review based on the methodological framework proposed by Whittemore and Knafl (2005), with searches conducted in the PubMed, Cochrane Library, and VHL databases, including 15 articles published between 2020 and 2026. The results demonstrated that PRP increases the likelihood of complete chronic wound closure by 5.32 times, with a median wound area reduction of 47.5% in venous ulcers, in addition to significant improvement in diabetic foot ulcers and in pediatric, oral, and general surgical procedures. The integration of PRP with smart biomaterials, such as hydrogels and nanoparticles, represents the current frontier of regenerative medicine. It is concluded that PRP is a safe, effective, and cost-effective therapy whose full potential depends on the implementation of rigorous operational protocols and the development of large-scale multicenter clinical trials.
Zitieren
APA
Mundim, L. R. P., Ferreira, A. L. C., David, C. M., Rubiano, D. L. M. C., Corrêa, G. L. A., Silva, J. B. D. L., Gama, V. C. D., Cesar, P. V. O., Machado, P. A. E., & Castro, V. L. M. (2026). Uso do plasma rico em plaquetas na cicatrização cirúrgica: evidências e aplicações clínicas. Revista ft, 30(161), 01-12. https://doi.org/10.69849/30c4gz39
Vancouver
Mundim LRP, Ferreira ALC, David CM, Rubiano DLMC, Corrêa GLA, Silva JBDL, et al. Uso do plasma rico em plaquetas na cicatrização cirúrgica: evidências e aplicações clínicas. Revista ft. 2026;30(161):01-12. doi:10.69849/30c4gz39
BibTeX
@article{Mundim2026,
author = {Mundim, Luca Rodrigues Pereira and Ferreira, Ana Luísa Carvalho and David, Clara Mendes and Rubiano, Daniel Leal Mathias Castro and Corrêa, Gabrielle Luigi Andrade and Silva, Julia Bianchi de Lellis and Gama, Victória Carvalho da and Cesar, Pedro Vinicius Ostrowski and Machado, Pedro Arthur Elias and Castro, Valéria Leal Mathias},
title = {Uso do plasma rico em plaquetas na cicatrização cirúrgica: evidências e aplicações clínicas},
journal = {Revista ft},
year = {2026},
volume = {30},
number = {161},
pages = {01--12},
doi = {10.69849/30c4gz39}
}
EUVIMED